1. Home
  2. INBS vs SNTI Comparison

INBS vs SNTI Comparison

Compare INBS & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intelligent Bio Solutions Inc.

INBS

Intelligent Bio Solutions Inc.

N/A

Current Price

$1.55

Market Cap

6.5M

Sector

Health Care

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$0.09

Market Cap

5.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INBS
SNTI
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
5.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
INBS
SNTI
Price
$1.55
$0.09
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $13.50
AVG Volume (30 Days)
36.1K
★ 1.2M
Earning Date
11-10-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.31
EPS
★ N/A
N/A
Revenue
★ $1,980,484.00
N/A
Revenue This Year
$44.72
$127.27
Revenue Next Year
$44.26
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.54
$0.09
52 Week High
$24.90
$57.60

Technical Indicators

Market Signals
Indicator
INBS
SNTI
Relative Strength Index (RSI) 41.55 14.24
Support Level $1.44 N/A
Resistance Level $1.86 $0.24
Average True Range (ATR) 0.18 0.02
MACD -0.04 0.23
Stochastic Oscillator 5.88 2.81

Price Performance

Historical Comparison
INBS
SNTI

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: